课题基金 / 基金详情

CELLULAR IMMUNE RESPONSES TO SUBUNIT IMMUNODEFICIENCY VIRUS VACCINES

CELLULAR IMMUNE RESPONSES TO SUBUNIT IMMUNODEFICIENCY VIRUS VACCINES
亚单位免疫缺陷病毒疫苗的细胞免疫反应
批准号:
6299486
负责人:
PHILIP D GREENBERG
金额:
$34.34万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2000
资助国家:
美国
项目状态:
已结题
起止时间:
2000-01-01 至 2000-12-31

项目摘要

项目成果

PHILIP D GREENBERG的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Advances in the development of a vaccine for HIV have been substantial. New vaccine vectors to deliver viral immunogens have been designed, vaccine preparations with enhanced immunogenicity have been produced based on a better understanding of the mechanisms of in vivo processing of antigens, new non-human primate models for HIV infection have been developed, and protective immunity in vaccinated non-human primates has been demonstrated under defined challenge conditions. Although many immunologic effector mechanisms with activity against HIV have been identified, the nature of the host immune responses necessary and sufficient for mediating protection have not been precisely defined. Characterizing such protective responses is essential to provide direction and establish immunologic goals for candidate vaccines. Studies are proposed in this project to continue our efforts to evaluate the role of specific components of vaccine-induced CD4+ and CD8+ T cell responses in protective immunity, determine the immunologic and virologic reasons why potentially protective T cell responses successfully or unsuccessfully resolve a viral challenge, and examine methods to improve the efficiency of T cell activation during vaccination. The studies will be performed in a non-human primate model with SHIV, a chimeric virus comprised of elements of HIV-1 and SIV, as the challenge virus. The specific aims are to: 1. evaluate the function, specificity, magnitude, and durability of T cell responses elicited by candidate vaccines; 2. correlate the T cell responses elicited by vaccines with the outcome of challenge with SHIV; 3. analyze the immunologic basis for failure of protection in vaccinated hosts; 4. evaluate the importance of CD4+ and CD8+ T cell subsets in protection by using adoptive T cell transfer to selectively enhance individual responses; and 5. examine new strategies designed to augment T cell responses elicited by candidate vaccines.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Project 1: Transgenic TCR-mediated tumor therapy
  • 批准号:
    10380817
  • 项目类别:
  • 资助金额:
    $89.93万
  • 财政年份:
    2019
  • 负责人:
    PHILIP D GREENBERG
  • 依托单位:
Project 1: Transgenic TCR-mediated tumor therapy
  • 批准号:
    10629190
  • 项目类别:
  • 资助金额:
    $57.96万
  • 财政年份:
    2019
  • 负责人:
    PHILIP D GREENBERG
  • 依托单位:
Chromatin states encoding fate commitment and plasticity of tolerant CD8 T cells
  • 批准号:
    8568389
  • 项目类别:
  • 资助金额:
    $18.15万
  • 财政年份:
    2013
  • 负责人:
    PHILIP D GREENBERG
  • 依托单位:
Chromatin states encoding fate commitment and plasticity of tolerant CD8 T cells
  • 批准号:
    8667993
  • 项目类别:
  • 资助金额:
    $23.18万
  • 财政年份:
    2013
  • 负责人:
    PHILIP D GREENBERG
  • 依托单位:
海外基金